| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CDXC Stock Overview
ChromaDex Corporation operates as a bioscience company focusing on healthy aging.
ChromaDex Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.69 |
| 52 Week High | US$8.75 |
| 52 Week Low | US$1.51 |
| Beta | 1.7 |
| 1 Month Change | -5.59% |
| 3 Month Change | 6.29% |
| 1 Year Change | -80.21% |
| 3 Year Change | -60.24% |
| 5 Year Change | -48.48% |
| Change since IPO | -84.98% |
Recent News & Updates
ChromaDex wins patent challenge as US regulator rejects Thorne Research's demand to invalidate patent
ChromaDex (NASDAQ:CDXC) said Thorne Research lost a patent challenge related to U.S. Patent No. 8,197,807 which is for compositions including nicotinamide riboside ChromaDex noted that it is the exclusive supplier of nicotinamide riboside chloride, Niagen — a supplement. The company said the U.S. Patent & Trademark Office's Patent Trial and Appeal Board (PTAB) rejected Thorne Research's attempt to invalidate the 807 patent. ChromaDex (CDXC) said it holds an exclusive license to the 807 patent for compositions including nicotinamide riboside (NR) from the Trustees of Dartmouth College. The decision, if upheld upon appeal, precludes Thorne from raising arguments before the PTAB in the New York District Court lawsuit brought by ChromaDex alleging that Thorne infringed the 807 patent, the company said in an Aug. 15 press release.
Shareholder Returns
| CDXC | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -10.6% | 1.9% | 3.2% |
| 1Y | -80.2% | -19.8% | -10.2% |
Return vs Industry: CDXC underperformed the US Life Sciences industry which returned -19.8% over the past year.
Return vs Market: CDXC underperformed the US Market which returned -10.2% over the past year.
Price Volatility
| CDXC volatility | |
|---|---|
| CDXC Average Weekly Movement | 14.6% |
| Life Sciences Industry Average Movement | 11.0% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CDXC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: CDXC's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 115 | Rob Fried | https://www.chromadex.com |
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
ChromaDex Corporation Fundamentals Summary
| CDXC fundamental statistics | |
|---|---|
| Market Cap | US$115.81m |
| Earnings (TTM) | -US$28.32m |
| Revenue (TTM) | US$69.06m |
1.7x
P/S Ratio-4.1x
P/E RatioIs CDXC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDXC income statement (TTM) | |
|---|---|
| Revenue | US$69.06m |
| Cost of Revenue | US$27.04m |
| Gross Profit | US$42.02m |
| Other Expenses | US$70.34m |
| Earnings | -US$28.32m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.41 |
| Gross Margin | 60.85% |
| Net Profit Margin | -41.01% |
| Debt/Equity Ratio | 0% |
How did CDXC perform over the long term?
See historical performance and comparison